Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics
- 1 Colorado State University, United States
- 2 Fraunhofer-Institute for Applied Polymer Research , Germany
Published On: 13 September 2019
Copyright: © 2020 Callie M. Blase, Brandon K. Rouault, Maia B. Zoller, Joshua V. Luff, Emma J. Lerch, Brynn N. Lauterbachq, Mark A. Brown, Joachim Storsberg and Christian Schmidt. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics.
- Commercial Exclusivity
- Immunologic Agents
- Antibody-based Therapeutics